Keynote Financial Services LLC Has $1.05 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Keynote Financial Services LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,577 shares of the biopharmaceutical company’s stock after purchasing an additional 141 shares during the quarter. Keynote Financial Services LLC’s holdings in Gilead Sciences were worth $1,054,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Manning & Napier Advisors LLC bought a new stake in shares of Gilead Sciences in the second quarter valued at about $25,328,000. Legal & General Group Plc lifted its position in Gilead Sciences by 0.8% in the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after purchasing an additional 93,068 shares during the period. IRON Financial LLC acquired a new stake in Gilead Sciences during the third quarter worth $830,000. GSA Capital Partners LLP bought a new stake in Gilead Sciences in the 1st quarter valued at $462,000. Finally, Wealth Enhancement Advisory Services LLC raised its stake in shares of Gilead Sciences by 13.1% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock valued at $19,630,000 after buying an additional 33,162 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on GILD shares. Robert W. Baird lifted their target price on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research report on Thursday. Truist Financial lifted their price objective on Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a report on Thursday, August 15th. JPMorgan Chase & Co. increased their target price on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday. Evercore ISI raised shares of Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Finally, Oppenheimer upped their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Thursday. Eleven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $90.05.

Gilead Sciences Trading Up 6.8 %

Shares of NASDAQ GILD opened at $97.90 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.32. The firm has a market capitalization of $121.88 billion, a P/E ratio of 119.39, a P/E/G ratio of 3.13 and a beta of 0.17. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95. The company’s 50 day simple moving average is $84.58 and its 200 day simple moving average is $74.67.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The company had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the prior year, the business posted $2.29 EPS. The firm’s quarterly revenue was up 7.0% on a year-over-year basis. On average, analysts predict that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 5,490 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the sale, the insider now directly owns 114,979 shares in the company, valued at $8,506,146.42. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the transaction, the insider now owns 114,979 shares of the company’s stock, valued at $8,506,146.42. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the sale, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 62,437 shares of company stock worth $5,374,825. Insiders own 0.29% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.